Anzeige
Meldung des Tages: Freitagabend nachbörslich veröffentlicht – was der Markt erst am Montag sieht

Roche Holding Aktie News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
356,00 CHF
+3,40 CHF
+0,96%
388,63 € 30.01.26
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
9,70 CHF
Dividendenrendite
2,68%
neu: Nachhaltigkeits-Score
48 %
Index-Zuordnung
-

Roche Holding News

18.12.24 - GlobeNewswire
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution
Roche launches its cobas ® Mass Spec solution, bringing mass spectrometry to the routine clinical lab Clinical mass spectrometry testing offers unparalleled sensitivity and ...
13.12.24 - GlobeNewswire
Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vials Vabysmo has demonstrated ...
13.12.24 - GlobeNewswire
Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities
The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings ...
10.12.24 - GlobeNewswire
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
Long-term data confirm fixed-​duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-​world data suggesting reduced treatment-​related ...
09.12.24 - GlobeNewswire
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of ...
08.12.24 - GlobeNewswire
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-...
05.12.24 - GlobeNewswire
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Application is based on data from the phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall ...
26.11.24 - GlobeNewswire
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-​in-class therapies across oncology, immunology, and neurology, uniquely ...
05.11.24 - GlobeNewswire
Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66 th American ...
31.10.24 - GlobeNewswire
Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease
New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s disease related amyloid pathology with very good ...
31.10.24 - GlobeNewswire
New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer
Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared ...
23.10.24 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months
Group sales grew by 6% 1 at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding ...
23.10.24 - GlobeNewswire
[Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6%
Konzernverkäufe stiegen in den ersten neun Monaten um 6% 1 zu konstanten Wechselkursen (CER; 2% in CHF) dank hoher Nachfrage nach Medikamenten und Diagnostika; ohne ...
18.10.24 - GlobeNewswire
Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who ...
14.10.24 - GlobeNewswire
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
Positive data confirm Evrysdi efficacy and safety in children first treated pre-​symptomatically before six weeks of age, with most achieving motor milestones similar to children ...
11.10.24 - GlobeNewswire
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-​free survival compared with palbociclib and ...
10.10.24 - GlobeNewswire
Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) ...
26.09.24 - GlobeNewswire
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
24.09.24 - GlobeNewswire
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
New TAGS (Temperature-​Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput ...
23.09.24 - GlobeNewswire
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
Roche’s CINtec PLUS Cytology is the only FDA-​approved and CE-marked dual-​stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-...

Newssuche

Videos

newspaper
29.01.26 -10,12%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »